<Record>
<Term>Gallium Ga 68 F(ab')2-Trastuzumab</Term>
<SemanticType>Pharmacologic Substance</SemanticType>
<ParentTerm>Radioimmunoconjugate</ParentTerm>
<ClassificationPath>Chemicals_and_Drugs_Kind/Drug, Food, Chemical or Biomedical Material/Pharmacologic Substance/Radiopharmaceutical Compound/Radioimmunoconjugate/Gallium Ga 68 F(ab')2-Trastuzumab</ClassificationPath>
<BroaderTerm>Radioimmunoconjugate</BroaderTerm>
<BroaderTerm>Radiopharmaceutical Compound</BroaderTerm>
<BroaderTerm>Chemicals_and_Drugs_Kind</BroaderTerm>
<BroaderTerm>Gallium Ga 68 F(ab')2-Trastuzumab</BroaderTerm>
<BroaderTerm>Pharmacologic Substance</BroaderTerm>
<BroaderTerm>Drug, Food, Chemical or Biomedical Material</BroaderTerm>
<Synonym>Gallium Ga 68 F(ab')2-Trastuzumab</Synonym>
<Synonym>HERScan</Synonym>
<Description>A radioimmunoconjugate consisting of a trastuzumab fragment labeled with the positron-emitting radioisotope gallium Ga 68 with radioisotopic and antibody activities. Upon administration, Ga-68-labeled F(ab')2-trastuzumab may bind to HER2-positive tumor cells, allowing radioimmunolocalization with positron emission tomography (PET). Trastuzumab is a recombinant humanized monoclonal antibody that selectively binds to the extracellular domain of human epidermal growth factor receptor 2 (HER2), overexpressed by many adenocarcinomas, particularly breast adenocarcinomas.</Description>
<Source>NCI Thesaurus</Source>
</Record>
